The level of deletion 17p and bi-allelic inactivation of TP53 has a significant impact on clinical outcome in multiple myeloma

被引：62
|
作者：
Thanendrarajan, Sharmilan [1 ]
Tian, Erming [1 ]
Qu, Pingping [2 ]
Mathur, Pankaj [1 ]
Schinke, Carolina [1 ]
van Rhee, Frits [1 ]
Zangari, Maurizio [1 ]
Rasche, Leo [1 ]
Weinhold, Niels [1 ]
Alapat, Daisy [3 ]
Bellamy, William [3 ]
Ashby, Cody [1 ]
Mattox, Sandra [1 ]
Epstein, Joshua [1 ]
Yaccoby, Shmuel [1 ]
Barlogie, Bart [1 ]
Hoering, Antje [2 ]
Bauer, Michael [1 ]
Walker, Brian A. [1 ]
Davies, Faith E. [1 ]
Morgan, Gareth J. [1 ]
机构：
[1] Univ Arkansas Med Sci, Myeloma Inst, Little Rock, AR 72205 USA
[2] Cancer Res & Biostat Seattle, Seattle, WA USA
[3] Univ Arkansas Med Sci, Dept Pathol, Little Rock, AR 72205 USA
来源：
HAEMATOLOGICA | 2017年 / 102卷 / 09期
关键词：
IN-SITU HYBRIDIZATION; TOTAL THERAPY; HIGH-RISK; EXPRESSION; RELAPSE; SYSTEM;
D O I：
10.3324/haematol.2017.168872
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E364 / E367
页数：4
相关论文
共 50 条
  • [1] Poor Overall Survival in Hyperhaploid Multiple Myeloma Is Defined By Double-Hit Bi-Allelic Inactivation of TP53
    Ashby, Cody
    Wang, Yan
    Tytarenko, Ruslana G.
    Schinke, Carolina D.
    Thanendrarajan, Sharmilan
    Zangari, Maurizio
    van Rhee, Frits
    Davies, Faith E.
    Sawyer, Jeffery R.
    Morgan, Gareth
    Walker, Brian A.
    BLOOD, 2018, 132
  • [2] Large deletions (>10.9 MB) in 17p and bi-allelic TP53 inactivation events in newly-diagnosed multiple myeloma are associated with higher clonal cell fraction and poor prognosis
    Towfic, Fadi
    Thakurta, Anjan
    Flynt, Erin
    Walker, Brian
    Morgan, Gareth
    Bisht, Kamlesh
    Jeyaraju, Danny
    Ortiz, Maria
    Mavrommatis, Konstantinos
    Hsu, Chih-Chao
    Gooding, Sarah
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E81 - E81
  • [3] Mutations in TP53 are exclusively associated with del(17p) in multiple myeloma
    Lode, Laurence
    Eveillard, Marion
    Trichet, Valerie
    Soussi, Thierry
    Wuilleme, Soraya
    Richebourg, Steven
    Magrangeas, Florence
    Ifrah, Norbert
    Campion, Loic
    Traulle, Catherine
    Guilhot, Francois
    Caillot, Denis
    Marit, Gerald
    Mathiot, Claire
    Facon, Thierry
    Attal, Michel
    Harousseau, Jean-Luc
    Moreau, Philippe
    Minvielle, Stephane
    Avet-Loiseau, Herve
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 (11): : 1973 - 1976
  • [4] Impact of TP53 mutation and 17p deletion in mantle cell lymphoma
    Halldorsdottir, A. M.
    Lundin, A.
    Murray, F.
    Mansouri, L.
    Knuutila, S.
    Sundstrom, C.
    Laurell, A.
    Ehrencrona, H.
    Sander, B.
    Rosenquist, R.
    LEUKEMIA, 2011, 25 (12) : 1904 - 1908
  • [5] Impact of TP53 mutation and 17p deletion in mantle cell lymphoma
    A M Halldórsdóttir
    A Lundin
    F Murray
    L Mansouri
    S Knuutila
    C Sundström
    A Laurell
    H Ehrencrona
    B Sander
    R Rosenquist
    Leukemia, 2011, 25 : 1904 - 1908
  • [6] Multiple Myeloma with a Deletion of Chromosome 17p: TP53 Mutations Are Highly Prevalent and Negatively Affect Prognosis
    Bruinink, Davine Hofste Op
    Remco, Hoogenboezem
    Sanders, Mathijs A.
    Wardell, Christopher P.
    Ashby, Cody
    Bindels, Eric M. J.
    Erpelinck-Verschueren, Claudia
    van Strien, Paulette
    Koenders, Jasper
    Kavelaars, Francois G.
    He, Jie
    Bailey, Mark
    Mughal, Tariq I.
    Misund, Kristine
    Beverloo, Berna
    van der Holt, Bronno
    Touw, Ivo
    Waage, Anders
    Avet-Loiseau, Herve
    Jackson, Graham H.
    Morgan, Gareth J.
    Walker, Brian A.
    Sonneveld, Pieter
    BLOOD, 2016, 128 (22)
  • [7] Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival
    Chin, M.
    Sive, J. I.
    Allen, C.
    Roddie, C.
    Chavda, S. J.
    Smith, D.
    Blombery, P.
    Jones, K.
    Ryland, G. L.
    Popat, R.
    Rismani, A.
    D'Sa, S.
    Rabin, N.
    Gale, R. E.
    Yong, K. L.
    BLOOD CANCER JOURNAL, 2017, 7 : e610 - e610
  • [8] Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survival
    M Chin
    J I Sive
    C Allen
    C Roddie
    S J Chavda
    D Smith
    P Blombery
    K Jones
    G L Ryland
    R Popat
    A Rismani
    S D'Sa
    N Rabin
    R E Gale
    K L Yong
    Blood Cancer Journal, 2017, 7 : e610 - e610
  • [9] TP53 mutation and 17p deletion are associated with poor survival in patients with CLL irrespective of the inactivation of the other allele by deletion or TP53 mutation:: Results from a single center analysis
    Zenz, T.
    Haebe, S.
    Kroeber, A.
    Benner, A.
    Kienle, D.
    Buehler, A.
    Denzel, T.
    Winkler, D.
    Doehner, H.
    Stilgenbauer, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 35 - 35
  • [10] 17p Deletion in CLL: Detailed Analysis of TP53 Mutations, Alternative Mechanisms of p53 Inactivation, Clone Size and Clonal Evolution
    Zenz, Thorsten
    Sarno, Antonio
    Haebe, Sonja
    Denzel, Tina
    Mohr, Julia
    Vollmer, Dominik
    Heuberger, Maria
    Winkler, Dirk
    Kienle, Dirk
    Buehler, Andreas
    Truong, Sim
    Patten, Nancy
    Hallek, Michael
    Doehner, Hartmut
    Stilgenbauer, Stephan
    BLOOD, 2008, 112 (11) : 291 - 291
12345